Altered macrophage function is associated with severe Burkholderia pseudomallei infection in a murine model of type 2 diabetes

Microbes and Infection

Volumn 13, Issue 14-15, 2011, Pages 1177-1184

  Hodgson, Kelly A ^a   Morris, Jodie L ^a   Feterl, Marshall L ^a   Govan, Brenda L ^a   Ketheesan, Natkunam ^a  

^a JAMES COOK UNIVERSITY   (Australia)

Author keywords

Burkholderia pseudomallei; Host pathogen interactions; Macrophage; Melioidosis; Type 2 Diabetes

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BURKHOLDERIA PSEUDOMALLEI; COMORBIDITY; CONTROLLED STUDY; DENDRITIC CELL; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; HYPERGLYCEMIA; MACROPHAGE FUNCTION; MELIOIDOSIS; NEUTROPHIL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY BURST; SPLEEN;

ANIMALS; BLOOD GLUCOSE; BURKHOLDERIA PSEUDOMALLEI; CELLS, CULTURED; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; HYPERSENSITIVITY, DELAYED; INFLAMMATION; INTERLEUKIN-1BETA; MACROPHAGES, PERITONEAL; MELIOIDOSIS; MICE; MICE, TRANSGENIC; NEUTROPHILS; RESPIRATORY BURST; SPLEEN; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA;

BACTERIA (MICROORGANISMS); BURKHOLDERIA PSEUDOMALLEI; MURINAE; MUS;

EID: 81155150056     PISSN: 12864579     EISSN: 1769714X     Source Type: Journal    
DOI: 10.1016/j.micinf.2011.07.008     Document Type: Article

References (37)

1. van der Poll T., Opal S.M. Host-pathogen interactions in sepsis. Lancet Infect. Dis. 2008, 8:32-43.
2. Currie B.J., Ward L., Cheng A.C. The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year darwin prospective study. PLoS Negl Trop. Dis. 2010, 4:e900.
3. Currie B.J., Fisher D.A., Howard D.M., Burrow J.N., Lo D., Selva-Nayagam S., Anstey N.M., Huffam S.E., Snelling P.L., Marks P.J., Stephens D.P., Lum G.D., Jacups S.P., Krause V.L. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin. Infect. Dis. 2000, 31:981-986.
4. Limmathurotsakul D., Wongratanacheewin S., Teerawattanasook N., Wongsuvan G., Chaisuksant S., Chetchotisakd P., Chaowagul W., Day N.P., Peacock S.J. Increasing incidence of human melioidosis in Northeast Thailand. Am. J. Trop. Med. Hyg. 2010, 82:1113-1117.
5. Saravu K., Mukhopadhyay C., Vishwanath S., Valsalan R., Docherla M., Vandana K.E., Shastry B.A., Bairy I., Rao S.P. Melioidosis in southern India: epidemiological and clinical profile. Southeast Asian J. Trop. Med. Public Health 2010, 41:401-409.
6. Cheng A.C., Limmathurotsakul D., Chierakul W., Getchalarat N., Wuthiekanun V., Stephens D.P., Day N.P., White N.J., Chaowagul W., Currie B.J., Peacock S.J. A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. Clin. Infect. Dis. 2007, 45:308-314.
7. Barnes J.L., Ketheesan N. Development of protective immunity in a murine model of melioidosis is influenced by the source of Burkholderia pseudomallei antigens. Immunol. Cell Biol. 2007, 85:551-557.
8. Rozen S., Skaletsky H. Primer3 on the WWW for general users and for biologist programmers 2000, Humana Press, Totowa.
9. Williams N.L., Kloeze E., Govan B.L., Korner H., Ketheesan N. Burkholderia pseudomallei enhances maturation of bone marrow-derived dendritic cells. Trans. R Soc. Trop. Med. Hyg. 2008, 102(Suppl. 1):S71-S75.
10. Williams N.L., Morris J.L., Rush C., Govan B.L., Ketheesan N. Impact of streptozotocin-induced diabetes on functional responses of dendritic cells and macrophages towards Burkholderia pseudomallei. FEMS Immunol. Med. Microbiol. 2011, 61:218-227.
11. Barnes J.L., Williams N.L., Ketheesan N. Susceptibility to Burkholderia pseudomallei is associated with host immune responses involving tumor necrosis factor receptor-1 (TNFR1) and TNF receptor-2 (TNFR2). FEMS Immunol. Med. Microbiol. 2008, 52:379-388.
12. Ketheesan N., Barnes J.L., Ulett G.C., VanGessel H.J., Norton R.E., Hirst R.G., LaBrooy J.T. Demonstration of a cell-mediated immune response in melioidosis. J. Infect. Dis. 2002, 186:286-289.
13. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
14. Hassan M.R., Pani S.P., Peng N.P., Voralu K., Vijayalakshmi N., Mehanderkar R., Aziz N.A., Michael E. Incidence, risk factors and clinical epidemiology of melioidosis: a complex socio-ecological emerging infectious disease in the Alor Setar region of Kedah, Malaysia. BMC Infect. Dis. 2010, 10:302.
15. Simpson A.J., Newton P.N., Chierakul W., Chaowagul W., White N.J. Diabetes mellitus, insulin, and melioidosis in Thailand. Clin. Infect. Dis. 2003, 36:e71-e72.
16. McDermott R.A., Li M., Campbell S.K. Incidence of type 2 diabetes in two Indigenous Australian populations: a 6-year follow-up study. Med. J. Aust. 2010, 192:562-565.
17. Muller L.M., Gorter K.J., Hak E., Goudzwaard W.L., Schellevis F.G., Hoepelman A.I., Rutten G.E. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin. Infect. Dis. 2005, 41:281-288.
18. Alamgir S., Volkova N.B., Peterson M.W. Prognostic value of low blood glucose at the presentation of E. coli bacteremia. Am. J. Med. 2006, 119:952-957.
19. Filkins J.P., Cornell R.P. Depression of hepatic gluconeogenesis and the hypoglycemia of endotoxin shock. Am. J. Physiol. 1974, 227:778-781.
20. Koh G.C., Maude R.R., Schreiber M.F., Limmathurotsakul D., Wiersinga W.J., Wuthiekanun V., Lee S.J., Mahavanakul W., Chaowagul W., Chierakul W., White N.J., van der Poll T., Day N.P., Dougan G., Peacock S.J. Glyburide is anti-inflammatory and associated with reduced mortality in melioidosis. Clin. Infect. Dis. 2011, 52:717-725.
21. Geerlings S.E., Hoepelman A.I. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol. Med. Microbiol. 1999, 26:259-265.
22. Leakey A.K., Ulett G.C., Hirst R.G. BALB/c and C57Bl/6 mice infected with virulent Burkholderia pseudomallei provide contrasting animal models for the acute and chronic forms of human melioidosis. Microb. Pathog. 1998, 24:269-275.
23. Breitbach K., Klocke S., Tschernig T., van Rooijen N., Baumann U., Steinmetz I. Role of inducible nitric oxide synthase and NADPH oxidase in early control of Burkholderia pseudomallei infection in mice. Infect. Immun. 2006, 74:6300-6309.
24. Jones A.L., Beveridge T.J., Woods D.E. Intracellular survival of Burkholderia pseudomallei. Infect. Immun. 1996, 64:782-790.
25. Barnes J.L., Warner J., Melrose W., Durrheim D., Speare R., Reeder J.C., Ketheesan N. Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. Clin. Immunol. 2004, 113:22-28.
26. Liu B.F., Miyata S., Kojima H., Uriuhara A., Kusunoki H., Suzuki K., Kasuga M. Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end products. Diabetes 1999, 48:2074-2082.
27. Utaisincharoen P., Tangthawornchaikul N., Kespichayawattana W., Chaisuriya P., Sirisinha S. Burkholderia pseudomallei interferes with inducible nitric oxide synthase (iNOS) production: a possible mechanism of evading macrophage killing. Microbiol. Immunol. 2001, 45:307-313.
28. Utaisincharoen P., Tangthawornchaikul N., Kespichayawattana W., Anuntagool N., Chaisuriya P., Sirisinha S. Kinetic studies of the production of nitric oxide (NO) and tumour necrosis factor-alpha (TNF-alpha) in macrophages stimulated with Burkholderia pseudomallei endotoxin. Clin. Exp. Immunol. 2000, 122:324-329.
29. Wetzler C., Kampfer H., Stallmeyer B., Pfeilschifter J., Frank S. Large and sustained induction of chemokines during impaired wound healing in the genetically diabetic mouse: prolonged persistence of neutrophils and macrophages during the late phase of repair. J. Invest. Dermatol. 2000, 115:245-253.
30. Khanna S., Biswas S., Shang Y., Collard E., Azad A., Kauh C., Bhasker V., Gordillo G.M., Sen C.K., Roy S. Macrophage dysfunction impairs resolution of inflammation in the wounds of diabetic mice. PLoS One 2010, 5:e9539.
31. Naguib G., Al-Mashat H., Desta T., Graves D.T. Diabetes prolongs the inflammatory response to a bacterial stimulus through cytokine dysregulation. J. Invest. Dermatol. 2004, 123:87-92.
32. Jacob A., Steinberg M.L., Yang J., Dong W., Ji Y., Wang P. Sepsis-induced inflammation is exacerbated in an animal model of type 2 diabetes. Int. J. Clin. Exp. Med. 2008, 1:22-31.
33. Rittirsch D., Flierl M.A., Ward P.A. Harmful molecular mechanisms in sepsis. Nat. Rev. Immunol. 2008, 8:776-787.
34. Ulett G.C., Ketheesan N., Hirst R.G. Proinflammatory cytokine mRNA responses in experimental Burkholderia pseudomallei infection in mice. Acta Trop. 2000, 74:229-234.
35. Suputtamongkol Y., Kwiatkowski D., Dance D.A., Chaowagul W., White N.J. Tumor necrosis factor in septicemic melioidosis. J. Infect. Dis. 1992, 165:561-564.
36. Chanchamroen S., Kewcharoenwong C., Susaengrat W., Ato M., Lertmemongkolchai G. Human polymorphonuclear neutrophil responses to Burkholderia pseudomallei in healthy and diabetic subjects. Infect. Immun. 2009, 77:456-463.
37. Vallerskog T., Martens G.W., Kornfeld H. Diabetic mice display a delayed adaptive immune response to Mycobacterium tuberculosis. J. Immunol. 2010, 184:6275-6282.